Analyst consensus rating
Corcept Therapeutics Analyst Rating: Buy
Direct answer
Corcept Therapeutics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $141.00.
Forecast evidence checked October 17, 2026.
Get free Corcept Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $110.16
- Average price target
- $141.00
- High price target
- $165.00
- Low price target
- $50.00
- Low target gap
- -54.6%
- Target upside
- +28%
- High target gap
- +49.8%
- Target range width
- 104.4%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Corcept Therapeutics?
Corcept Therapeutics has a verified Buy consensus. The same dataset has an average price target of $141.00.
How far are Corcept Therapeutics's low and high targets from the recorded price?
The low target implies -54.6%, while the high target implies +49.8%.
How many analysts are included in Corcept Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Corcept Therapeutics's target upside or downside calculated?
The average target of $141.00 is divided by the recorded price of $110.16, then one is subtracted to produce +28%. This does not guarantee a future return.
When was Corcept Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.